BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BBIO · as of Sep 30, 2025
Ownership Breakdown
429
Institutional Holders
▲ 33 vs Q2
$9.61B
Total Inst. Value
▲ $1.45B vs Q2
195.86M
Shares Outstanding
freeFloat 86.31%
185.14M
13F Shares Held
▼ 3.68M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BBIO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 16.83M | 8.83% | 8.83% | $874.26B | Nov 7, 2025 | ▲ 347.1K |
VIKING GLOBAL INVESTORS LP pharmaceutical preparations | 15.98M | 8.39% | 8.39% | $829.89B | Nov 14, 2025 | ▼ 2.58M |
BLACKROCK, INC. pharmaceutical preparations | 14.41M | 7.56% | 7.56% | $748.52B | Nov 12, 2025 | ▲ 151.7K |
KOHLBERG KRAVIS ROBERTS & CO. L.P. pharmaceutical preparations | 13.26M | 6.96% | 6.96% | $688.77B | Nov 14, 2025 | — held |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 8.74M | 4.59% | 4.59% | $453.96B | Nov 14, 2025 | ▼ 535.5K |
FARALLON CAPITAL MANAGEMENT LLC pharmaceutical preparations | 8.19M | 4.30% | 4.30% | $425.49B | Feb 17, 2026 | ▲ 292.0K |
AISLING CAPITAL MANAGEMENT LP pharmaceutical preparations | 6.09M | 3.20% | 3.20% | $316.29B | Nov 12, 2025 | ▲ 21.5K |
STATE STREET CORP pharmaceutical preparations | 5.61M | 2.94% | 2.94% | $291.19B | Nov 14, 2025 | ▼ 290.3K |
INVESCO LTD. pharmaceutical preparations | 3.93M | 2.06% | 2.06% | $204.05B | Nov 13, 2025 | ▲ 1.13M |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.91M | 2.05% | 2.05% | $203.11B | Nov 12, 2025 | ▲ 228.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+7.20M shares3
New Positions
first time holders22
Decreased
−10.48M shares0
Sold Out
fully exitedNet shares change (top 50)
3.28M
+7.20M / −10.48M
Net new holders
+3
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BBIO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
5
Buy transactions
35
Sell transactions
0.14
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 2,256 | $67.57 | $152.4K | 267.2K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 6,725 | $68.30 | $459.3K | 260.4K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 5,072 | $69.22 | $351.1K | 255.4K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 11,250 | $70.48 | $792.9K | 244.1K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 800 | $70.92 | $56.7K | 243.3K | Form 4 ↗ |
Trimarchi Thomas President and CFO | May 16, 2026 | Tax Withhold | 22,781 | $66.13 | $1.51M | 372.8K | Form 4 ↗ |
Trimarchi Thomas President and CFO | May 18, 2026 | Sale | 10,456 | $64.82 | $677.7K | 362.4K | Form 4 ↗ |
Trimarchi Thomas President and CFO | May 18, 2026 | Sale | 3,195 | $65.95 | $210.7K | 359.2K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 16, 2026 | Tax Withhold | 36,236 | $66.13 | $2.40M | 269.4K | Form 4 ↗ |
Apuli Maricel Chief Accounting Officer | May 16, 2026 | Tax Withhold | 4,714 | $66.13 | $311.7K | 129.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BridgeBio Pharma, Inc. (BBIO) is primarily owned by institutional investors, who hold approximately 94.5% of total shares outstanding. Company insiders own approximately 13.69%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of BridgeBio Pharma, Inc. is VANGUARD GROUP INC, holding approximately 16.83 million shares — equal to 8.83% of outstanding shares — as of September 30, 2025.
A total of 429 institutional investors currently hold BBIO stock, with a combined institutional value of approximately $9.61 billion as of the most recent 13F filing period.
Frequently asked questions
BBIO ownershipBridgeBio Pharma, Inc. (BBIO) is primarily owned by institutional investors, who hold approximately 94.5% of shares. The largest shareholder is VANGUARD GROUP INC with a 8.83% stake. Company insiders hold 13.69%. Data sourced from SEC Form 13F as of September 30, 2025.